12:00 AM
 | 
Apr 12, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Eladur transdur-bupivacaine: Phase IIb started

King began a double-blind, placebo-controlled Phase IIb trial to evaluate 3 Eladur patches administered every 72 hours for 12 weeks in 260 patients. King gained Eladur through its acquisition...

Read the full 122 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >